Scott Fettner

The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition

Ashok Rakhit, Michael Pantze, Scott Fettner et al. · European Journal of Clinical Pharmacology · 2007 · 122 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Phase I Trial of 40-kd Branched Pegylated Interferon Alfa-2a for Patients With Advanced Renal Cell Carcinoma

Robert J. Motzer, Ashok Rakhit, Michelle S. Ginsberg et al. · Journal of Clinical Oncology · 2001 · 101 citations

Medicine, Oncology, Pharmacology +17

Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA

Hisham Abdallah, Joy Hsu, Peng Lü et al. · The Journal of Clinical Pharmacology · 2016 · 96 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals

Jie Ling, Scott Fettner, Bert L. Lum et al. · Anti-Cancer Drugs · 2008 · 87 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Safety and Pharmacokinetic Characterization of Nacubactam, a Novel β-Lactamase Inhibitor, Alone and in Combination with Meropenem, in Healthy Volunteers

Navita L. Mallalieu, Erica Winter, Scott Fettner et al. · Antimicrobial Agents and Chemotherapy · 2020 · 63 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17